Clinical trial
Schizophrenia Trial of Aripiprazole
NCT00237913 · Otsuka Pharmaceutical Development & Commercialization, Inc., Industry · Completed
Key facts
| NCT number | NCT00237913 |
|---|---|
| Title | Schizophrenia Trial of Aripiprazole |
| Official title | A Multicenter, Randomized, Naturalistic, Open-Label Study Between Aripiprazole and Standard of Care in the Management of Community-Treated Schizophrenic Patients (Schizophrenia Trial of Aripiprazole - STAR) |
| Lead sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc., Industry |
| Collaborators | Otsuka America Pharmaceutical Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Aripiprazole, Olanzapine or Quetiapine or Risperidone |
| Enrollment | 700 |
| Start date | Jul 1, 2004 |
| Primary completion | Aug 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | Oct 13, 2005 |
| Last update posted | Nov 8, 2013 |
| Countries | Austria, Czechia, Denmark, Finland, France, Germany, Spain, Sweden, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: